



Universiteit
Leiden

The Netherlands

Advances in treatment and new insights in molecular biology of rectal cancer

Kapiteijn, Ellen

Citation

Kapiteijn, E. (2002, February 20). *Advances in treatment and new insights in molecular biology of rectal cancer*. Retrieved from <https://hdl.handle.net/1887/556>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/556>

Note: To cite this publication please use the final published version (if applicable).

CONTENTS

Chapter 1	General introduction and outline of this thesis.	11
PART I: ADVANCES IN TREATMENT		
Chapter 2	Local recurrence in patients with rectal cancer diagnosed between 1988 and 1992: a population-based study in the west Netherlands. <i>Eur J Surg Oncol 1998;24:528-535</i>	37
Chapter 3	European trials with Total Mesorectal Excision. <i>Sem Surg Oncol 2000;19:350-357</i>	51
Chapter 4	Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer. <i>J Clin Oncol (in press)</i>	63
Chapter 5	Impact of surgical training on recurrence and survival in rectal cancer. <i>Submitted</i>	77
Chapter 6	Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. <i>New Engl J Med 2001;345:638-646</i>	89
PART II: NEW INSIGHTS IN MOLECULAR BIOLOGY		
Chapter 7	Mechanisms of oncogenesis in colon versus rectal cancer. <i>J Pathol 2001;195:171-178</i>	101
Chapter 8	Diploid, microsatellite stable rectal tumours show diverse molecular phenotypes. <i>Submitted</i>	113
Chapter 9	p53 expression in human rectal tissue after radiotherapy: upregulation in normal mucosa versus functional loss in rectal carcinomas. <i>Int J Radiat Oncol Biol Phys (in press)</i>	129
Chapter 10	Loss of EpCAM expression is associated with increased local recurrence risk and low microvessel count with increased distant recurrence risk in rectal cancer. <i>Submitted</i>	141
Chapter 11	Summary and conclusive remarks	153
Chapter 12	Samenvatting en afsluitende opmerkingen	162
	Lijst van deelnemers TME-trial	169
	Publicaties	172
	Curriculum Vitae	174
	Bijlage	177

LIST OF ABBREVIATIONS

ACF	Aberrant Crypt Foci
APC	Adenomatous Polyposis Coli
APR	AbdominoPerineal Resection
CDGE	Constant Denaturant Gel Electrophoresis
CIN	Chromosomal INstability
CRAB	Cancer Recurrence And Blood transfusion
CT	ChemoTherapy
DCC	Deleted in Colorectal Cancer
DGGE	Denaturing Gradient Gel Electrophoresis
DPC4	Deleted in Pancreatic Cancer 4
DSS	Disease Specific Survival
EPL	Extended Pelvic Lymphadenectomy
FAP	Familial Adenomatous Polyposis
HNPCC	Hereditary Non-Polyposis Colorectal Cancer
IGF	Insulin-like Growth Factor
IKW	Integraal Kankercentrum West
IHC	ImmunoHistoChemistry
IMA	Inferior Mesenteric Artery
LAR	Low Anterior Resection
LND	Lymph Node Dissection
LOH	Loss Of Heterozygosity
LR	Local Recurrence
MCR	Mutational Cluster Region
MMR	MisMatch Repair
MSI	MicroSatellite Instability
OS	Overall Survival
PCR	Polymerase Chain Reaction
Pre/Postop	Pre/Postoperative
Pts	Patients
PTT	Protein Truncation Test
RT	RadioTherapy
SRCT	Swedish Rectal Cancer Trial
SSP	Sphincter Saving Procedure
TGF	Transforming Growth Factor
TME	Total Mesorectal Excision
Vs	Versus
WT	Wild Type

